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Abstract
Background: Human papillomavirus (HPV) capsids are composed of 72 pentamers of the major capsid protein L1, and an
unknown number of L2 minor capsid proteins. An N-terminal ‘‘external loop’’ of L2 contains cross-neutralizing epitopes, and
native HPV16 virions extracted from 20-day-old organotypic tissues are neutralized by anti-HPV16 L2 antibodies but virus
from 10-day-old cultures are not, suggesting that L2 epitopes are more exposed in mature, 20-day virions. This current study
was undertaken to determine whether cross-neutralization of other HPV types is similarly dependent on time of harvest and
to screen for the most effective cross-neutralizing epitope in native virions.
Methodology and Principal Findings: Neutralization assays support that although HPV16 L2 epitopes were only exposed in
20-day virions, HPV31 or HPV18 epitopes behaved differently. Instead, HPV31 and HPV18 L2 epitopes were exposed in 10-
day virions and remained so in 20-day virions. In contrast, presumably due to sequence divergence, HPV45 was not cross-
neutralized by any of the anti-HPV16 L2 antibodies. We found that the most effective cross-neutralizing antibody was a
polyclonal antibody named anti-P56/75 #1, which was raised against a peptide consisting of highly conserved HPV16 L2
amino acids 56 to 75.
Conclusions and Significance: This is the first study to determine the susceptibility of multiple, native high-risk HPV types
to neutralization by L2 antibodies. Multiple anti-L2 antibodies were able to cross-neutralize HPV16, HPV31, and HPV18. Only
neutralization of HPV16 depended on the time of tissue harvest. These data should inform attempts to produce a second-
generation, L2-based vaccine.
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Introduction
High-risk human Papillomavirus (HPV) virions are the etiologic
agents of numerous anogenital and oropharyngeal cancers [1,2].
Over99%of cervical cancers arecaused by persisent infections with
high-risk HPVs which accounts for the second highest cancer
burden in women worldwide next to breast cancer [1,2]. HPV
capsids contain a single, circular dsDNA genome of approximately
8 kb, which associates with histones to form a chromatin-like
structure [3,4]. The viral DNA is packaged within a nonenveloped,
icosahedral capsid composed of 72 pentamers of the major capsid
protein L1 and an unknown number of the minor capsid protein L2
[5,6]. High resolution images of bovine papillomavirus 1 (BPV1)
and HPV16 pseudovirions (PsV) suggest that the inner conical
hollow of L1 pentamers can be occluded with a monomer of L2
[5,6].Importantly,anN-terminal‘‘external loop’’ofL2existswhich
can be the target of neutralizing and cross-neutralizing antibodies
[7,8,9,10]. It is unknown if the external loop threads through the
center of L1 pentamers or between them [5,9].
We showed previously that organotypic culture-derived HPV16
virions exploited a tissue-spanning redox gradient that facilitated
assembly and maturation events in the context of the complete
papillomavirus life cycle [11,12]. Importantly, neutralization of
HPV16 by anti-L2 antibody RG-1 (a.a. 17-36) depended on the
maturation state of the virion [11,12]. Virions extracted from 20-
day-old tissue were neutralized more effectively than virions
extracted from 10 or 15-day-old tissue, which suggested that L2
loops were externalized over time [11,12]. Further, substitutions of
conserved N-terminal L2 cysteines for serine abrogated effective
neutralization of 20-day HPV16 native virions, lending support to
the hypothesis that redox and differentiation-dependent confor-
mational changes in L2 occur in the context of stratified and
differentiated human tissue [11,12].
The current study was undertaken to determine whether cross-
neutralization of other HPV types is dependent on the time of
tissue harvest and to determine the most effective cross-
neutralization epitope in L2 from native virions. We show that
although availability of HPV16 L2 epitopes for neutralization was
maximal in 20-day virions, HPV31 or HPV18 epitopes were
already maximally exposed at 10-days, and remained so in 20-day
samples. In contrast, HPV45 was not cross-neutralized by any of
the anti-HPV16 L2 antibodies presumably because of sequence
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polyclonal antibody named anti-P56/75 #1. Anti-P56/75 #1 was
raised against a peptide consisting of HPV16 L2 amino acids 56 to
75. This epitope was 100% similar and 90–100% identical in all
HPV types tested. These data are the first to determine the
susceptibility of native, high-risk HPV types to antibodies that
recognize cross-neutralizing, N-terminal, L2 epitopes, and should
inform attempts to produce a second-generation, L2-based
vaccine.
Results
Establishment of HPV16, HPV31, HPV18, and HPV45
containing stable cell lines
Stable cell lines that can synthesize HPV16, HPV31, HPV18,
and HPV45 organotypic culture-derived native virions were
described previously by our lab [11,13,14,15,16]. Briefly, these
cell lines were obtained by electroporating primary human
foreskin keratinocytes (HFKs) with linearized HPV16, HPV18,
and HPV45 full-length genomes and selecting immortalized stable
cell lines [11,14,15,16]. The CIN-612 9E cervical intraepithelial
neoplasia type I biopsy-derived cell line was utilized for the
production of HPV31 [13]. From these stable cell lines,
organotypic cultures were grown for 10 or 20-days, at which
point, crude viral preps (CVPs) were generated by dounce
homogenization in phosphate buffer, followed by salt extraction
of virions. As described previously, all CVPs were treated with
benzonase to remove free or susceptible virus-associated genomes
prior to performing additional experiments [11].
RT-qPCR-based neutralization and cross-neutralization of
10 and 20-day HPV16 and HPV31 virions
To compare the potential of the L2 external loop in the
evolutionarily related HPV types HPV16 and HPV31 as a
neutralization and cross-neutralization target, a panel of anti-
HPV16 L2 external loop-targeting antibodies that recognize
epitopes within amino acids 14–144 were obtained and utilized
in RT-qPCR-based neutralization assays [7,8,10]. Primers used
for qPCR-based assays can be seen in Tables S1 and S2. Table S3
and Fig. 1 list the origin of each antibody and their previously
published neutralization and cross-neutralization titers against
HPV16, HPV31, HPV18, and HPV45 pseudovirions (PsV). For
all experiments, antibodies were used at a 1:100 dilution for
neutralization of approximately 10 vge/cell of HPV16 and 100
vge/cell of HPV31. 1:100 dilutions of each antibody are usually
the highest concentration reported for neutralization tests of PsV,
quasivirions (QV), and organotypic culture-derived native virions
[7,8,10,12]. Even though 10-fold more vge/cell was used with
HPV31 compared to HPV16, this allowed for normalization of
RT-qPCR data, allowing amplification of nucleic acid at similar
Ct values (data not shown).
Surprisingly, even though all antibodies were raised against
either HPV16 L2 peptides or full-length HPV16 L2, none of these
antibodies neutralized 10-day HPV16 (Fig. 2A). In contrast, 20-
day HPV16 were neutralized by nearly all the antibodies, as each
reduced E1‘E4 expression about 60–80% compared to untreated
controls (Fig. 2A). The exception was anti-P96/115 #2, which did
not reduce E1‘E4 expression (Fig. 2A).
The neutralization profile of HPV31 was very different from
that of HPV16 (Fig 2B). Neutralization of 10-day HPV31
generated a profile very similar to that of 20-day HPV31
(Fig. 2B). HPV31 was not neutralized by anti-P14/27 #2, anti-
P18/38 #2, anti-P28/42 #2, anti-P61/75 #2, anti-P107/122
#1, or anti-P131/144 #2 (Fig. 2B). However, several of the
antibodies reduced E1‘E4 expression as much as 95% and others
to a lesser extent (Fig. 2B).
RT-qPCR-based cross-neutralization of 10 and 20-day
HPV18 and HPV45 virions
To assess the potential of the L2 external loop in the
evolutionarily related HPV types, HPV18 and HPV45 as a
cross-neutralization target, the panel of anti-HPV16 L2 external
loop-targeting antibodies that recognize epitopes within amino
acids 14–144 were utilized in RT-qPCR-based neutralization
assays (Table S3) [7,8,10]. For all experiments, antibodies were
utilized at a 1:100 dilution with 3,000 vge/cell of HPV18, or 50
vge/cell of HPV45. Even though 60-fold more vge/cell was
utilized with HPV18 compared to HPV45, this allowed for
normalization of RT-qPCR data, allowing amplification of nucleic
acid at similar Ct values (data not shown). This normalized
infections with HPV16 and HPV31 as well.
The neutralization profiles of 10 or 20-day HPV18 were very
similar. Several of the antibodies reduced E1‘E4 expression by 20–
95% (Fig. 3A). However, significant differences in neutralizing
activity were seen when neutralizing 10 compared to 20-day
HPV18 virions with anti-P28/42 #2 and anti-P90/111 #1,
making it difficult to make conclusions with these antibodies
(Fig. 3A). We also noted significant increases in infectivity when
HPV18 virions were pre-incubated with anti-P14/27 #2, anti-
P107/122 #1, and anti-P131/144 #2.
The neutralization profile of HPV45 was very different from all
of the other types tested in that it was resistant to neutralization at
either time of harvest regardless of the antibody tested (Fig. 3B).
We hypothesized that the inability to neutralize HPV45 was either
due to sequence divergence, or conformational differences in L2
epitopes compared to HPV16 that hindered antibody binding.
Although HPV45 was not neutralized, we found that the most
effective cross-neutralizing antibody was anti-P56/75 #1, which
neutralized 20-day HPV16 and cross-neutralized 10- and 20-day
HPV31 and HPV18.
Inefficient binding of anti-P56/75 #1 to HPV45 L2
Since HPV45 harvested at 10 and 20 days was resistant to cross-
neutralization by all 13 antibodies tested (Fig. 3B), the percent
identities and similarities of HPV31, HPV18, and HPV45 L2
epitopes were determined as compared to HPV16 L2 epitopes
(Table 1). Generally, susceptibility to cross-neutralization corre-
lated with the degree of conservation of a specific L2 epitope. For
example, anti-P64/81#1 cross-neutralized HPV31 and HPV18,
whose L2 epitopes share 83% identity, but anti-P64/81#1 didn’t
cross-neutralize HPV45 whose L2 epitope shares only 72%
identity with HPV16 (Table 1). This analysis assumes that L2
epitopes are equally exposed on the surface of the capsid of each
type and that antibody binds to L2 epitopes of each type to the
same extent. The anti-P56/75#1 epitope is 90–100% conserved
in HPV31, HPV18, and HPV45 compared to HPV16 (Table 1).
Yet anti-P56/75#1, which cross-neutralized 10 and 20-day
HPV31 and HPV18, failed to cross-neutralize 10 and 20-day
HPV45. The anti-P56/75#1 epitope in HPV45 L2 differs only in
two amino acid (i.e. T66S and I73V) than to HPV16 L2 (Fig. 1).
Since the HPV31 antiP56/75#1 epitope also has the I73V
substitution, the T66S substitution must have either singly or
additively altered the immunogenicity of the HPV45 anti-P56/
75#1 epitope (Fig. 1). Another possibility is that the anti-P56/
75#1 epitope is inaccessible to antibody binding in the context of
the complete HPV45 viral particle.
To determine if the failure of anti-P56/75#1 to cross-neutralize
HPV45 was due to the inability of the antibody to recognize a
Cross-Neutralization of Human Papillomaviruses
PLoS ONE | www.plosone.org 2 February 2011 | Volume 6 | Issue 2 | e16405slightly altered HPV45 L2 epitope, Western blot analyses of
reduced L1 and L2-containing HPV16, HPV31, HPV18, and
HPV45 VLPs were performed using anti-P56/75#1 to detect L2
(Fig. 4A). As seen in Fig. 4A, anti-P56/75#1 successfully
recognized HPV16, HPV31, HPV18, and HPV45 L2 linear
epitopes.
However, equivalent levels of immunoreactivity were not
observed after performing Western blot analysis on samples
loaded with equal amounts of HPV31 and HPV45 L2 protein
based on Coomassie Blue staining (Fig. 4B). Compared to HPV31
L2, there was a significant decrease in the binding of anti-P56/
75#1 to HPV45 L2, suggesting that the single T66S substitution
in the HPV45 anti-P56/75#1 epitope was sufficient to alter
immunogenicity. In contrast, 10-day HPV45 was neutralized over
90% by 1:100 dilutions of polyclonal antisera generated from
HPV45 L1/L2 VLPs, supporting that the failed neutralization
Figure 1. Alignment of HPV16, HPV31, HPV18, and HPV45 L2. The N-terminal 236 amino acids of HPV16 L2 were aligned against HPV31,
HPV18, and HPV45 L2 using NCBI BLAST. Asterisks denote 100% amino acid identity. Colons denote conservation of amino acid properties. Periods
denote conservation of some of the amino acids. White space denotes a lack of amino acid conservation. Grey shaded regions indicate stretches of N-
terminal amino acids that are exposed as antigens on the capsid surface. Black bars highlight N-terminal L2 peptides that were used to raise the
antibodies listed above them.
doi:10.1371/journal.pone.0016405.g001
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antibodies (data not shown). These results suggest that the inability
of anti-P56/75#1 to cross-neutralize HPV45 was due to lack of
binding to the slightly altered HPV45 L2 linear epitope, rather
than failure of the HPV45 L2 epitope to be conformationally
accessible to antibody binding.
Discussion
We showed previously that native virions exploit a tissue-
spanning redox gradient, which facilitated assembly and/or
maturation events in the context of the complete papillomavirus
life cycle [11]. Importantly, neutralization of HPV16 by the anti-
L2 antibody RG-1 was dependent on the maturation state of the
virion. Virions extracted from 20-day-old tissue were neutralized
more strongly than virions extracted from 10 or 15-day-old tissues,
suggesting that the L2 loop was externalized over time [11]. The
anti-HPV16 L2 antibodies anti-P14/27 #2 (a.a. 14–27), anti-P56/
75 #1 (a.a. 56–75), and #S910-1 (a.a. 1–88) also strongly
neutralized 20-day HPV16 but not 10-day HPV16 [12]. Here we
extended those observations, using a panel of anti-HPV16 L2
‘‘external loop’’ targeting antibodies to determine if the neutral-
ization of other HPV types depended on the time of virus harvest.
Both HPV31 and HPV18 extracted from either 10 or 20-day-old
tissue were cross-neutralized similarly. However, regardless of the
time of harvest, HPV45 was not cross-neutralized by any of the
HPV16 L2 antibodies.
We reasoned that sequence divergence in L2 epitopes rather
than the lack of proper display of those epitopes could explain the
lack of cross-neutralization. The epitope most conserved in the two
types is recognized by anti-P56/75 #1 and shares 90% percent
identity and 100% percent similarity. Furthermore, this HPV45
epitope differs from the HPV31 epitope by only a single amino
acid (i.e. T66S) and the anti-P56/75 #1 antibody cross-
neutralized both 10 and 20-day HPV31. Anti-P56/75 #1 strongly
reacted with the linear epitope of HPV31 but not HPV45. Thus,
the single, very conservative, T66S substitution was sufficient to
hinder recognition of HPV45 L2 by this antibody, consistent with
our hypothesis that the sequence changes are responsible for the
failure of at least some anti-HPV16 L2 antibodies to cross-react
with HPV45. Even with its failure to cross-neutralize HPV45, we
found that the most effective cross-neutralizing antibody was anti-
P56/75 #1, which did neutralize and cross-neutralize HPV16,
HPV31, and HPV18. Although anti-P56/75 #1 was unable to
neutralize HPV45, a concatemer, designated L2 11–8865, which
is composed of the conserved N-terminal sequence of amino acids
11–88 from L2 proteins of the distantly related HPV types 1, 5, 6,
16, and 18 did induce antibodies in both mice and rabbits. These
Figure 2. Neutralization of HPV16 (A) and cross-neutralization of HPV31 (B) CVPs with L2 antibodies. 50 ml of each 10 or 20-day CVP
was diluted 1:10 in HaCaT media with or without (–) a 1:100 dilution of each antibody. Neutralization reactions were incubated for 1 hour at 37uC
prior to infection of 5610
6 HaCaT cells. RNA was harvested and infectivity was assessed by measuring relative E1‘E4 expression by duplex RT-qPCR.
No antibody control values (–) were set to 1.0. Detailed information regarding the abbreviated antibodies #1-RG-1 can be seen in Table S3 and Fig. 1.
All experiments were performed in triplicate and standard error of the mean was calculated.
doi:10.1371/journal.pone.0016405.g002
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suggest that raising a multitype antibody response against L2 is an
effective technique to cross-neutralize a large number of
papillomavirus types.
We also compared previously published neutralization and
cross-neutralization data for HPV PsV to our data for native
virions derived from organotypic culture (Table S3) [7,8,10].
Significant differences were apparent (compare Figs. 2–3 to Table
S3). These comparisons encompass many publications and
experimental protocols, so the differences in neutralizing activity
between PsV and native virions most likely arise from method-
ological considerations rather than from physical properties of the
individual particles.
These experiments highlight the utility of N-terminal L2
epitopes in eliciting cross-neutralizing antibodies that can
neutralize infectivity of virions synthesized in stratifying and
differentiating human epithelial tissue. Many antibodies neutral-
ized 20-day HPV16 and cross-neutralized 10 or 20-day HPV31
and HPV18 in crude viral preparations, an environment which
represents the physiological state of natural infection much more
so than fractions of gradient-purified virus. The neutralization of
virus in crude viral preparations shows that the abundant
proteinaceous material in the prep does not interfere with
antibody reactivity against organotypic culture-derived native
virions. In addition, the failure of antibodies to neutralize HPV16
should not be a serious obstacle to the development of future L2-
based vaccines because 10-day HPV16 particles reside in the
suprabasal compartment of stratifying and differentiating human
epithelial tissue. Any transmission of these highly unstable particles
would require severe damage to release them from deep within the
tissue. Such extensive damage is likely a rare event. A more
concerning finding was that significant increases in infectivity were
observed when antibodies were pre-incubated with HPV18. At
present, the mechanism that led to the increase in infectivity is
unknown and should be thoroughly investigated.
Materials and Methods
Ethics Statement
The use of discarded human foreskin keratinocyte (HFK) tissues
to develop cell lines for these studies was approved by the
Institutional Review Board at the Pennsylvania State University
College of Medicine and by the Institutional Review Board at
Pinnacle Health Hospitals.
Keratinocyte cultures, and electroporation
Primary human foreskin keratinocytes (HFKs) were isolated
from newborn circumcision as described previously [13,14,15,16].
Briefly, keratinocytes were grown in 154 medium (Cascade
Biologics, Inc., Portland, OR) supplemented with Human
Keratinocyte Growth Supplement Kit (Cascade Biologics, Inc.).
Electroporations of HPV16, HPV18, and HPV45 in primary
Figure 3. Cross-neutralization of HPV18 (A) and HPV45 (B) CVPs with L2 antibodies. 50 ml of each 10 or 20-day CVP was diluted 1:10 in
HaCaT media with or without (–) a 1:100 dilution of each antibody. Neutralization reactions were incubated for 1 hour at 37uC prior to infection of
5610
6 HaCaT cells. RNA was harvested and infectivity was assessed by measuring relative E1‘E4 expression by duplex RT-qPCR. No antibody control
values (–) were set to 1.0. Detailed information regarding the abbreviated antibodies #1-RG-1 can be seen in Table S3 and Fig. 1. All experiments
were performed in triplicate and standard error of the mean was calculated.
doi:10.1371/journal.pone.0016405.g003
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[13,14,15,16]. Following electroporation, HPV-positive cell lines
were selected via immortalization as compared to HFKs that were
mock transfected. The HPV31-containing 9E cell line, obtained
from a low-grade CINI cervical lesion, has been described
previously [13].
Organotypic ‘‘raft’’ cultures
Immortalized HFK lines which stably maintained episomal
HPV16, HPV31, HPV18, and HPV45 DNA were grown in
monolayer culture using E medium in the presence of mitomycin
C-treated J2 3T3 feeder cells. Raft tissues were grown as
previously described [13,14,15,16]. Briefly, HPV16-containing
HFK lines were seeded onto rat tail type-1 collagen matrices
containing J2 3T3 feeder cells not treated with mitomycin C. After
epithelial attachment to the collagen matrices and growth to
confluence, matrices were lifted onto stainless steel grids. Once
lifted to the air-liquid interface, epithelial raft cultures were fed by
diffusion from underneath with E medium which lacked epidermal
growth factor (EGF) and was supplemented with 20 mM 1,2-
dioctanoyl-sn-glycerol (C8:0, Sigma Chemical, St. Louis, MO).
Raft cultures were allowed to stratify and differentiate for 10 and
20 days.
HPV isolation
For Optiprep fractionation, RT-PCR, RT-qPCR, and qPCR-
based DNA encapsidation assays, 3-raft crude viral preps (CVPs)
were prepared by dounce homogenization in 500 ml phosphate
buffer (0.05 M Na-phosphate [pH 8.0], 2 mM MgCl2). Homog-
enizers were rinsed with 250 ml phosphate buffer. 1.5 ml (375 units)
Benzonase (Sigma) was added to 750 ml of CVPs and incubated at
37uC for 1 hour. Samples were adjusted to 1 M NaCl by adding
130 ml ice cold 5 M NaCL. Then, samples were vortexed and
centrifuged at 4uC for 10 minutes at 10,500 rpm in a micro-
centrifuge. Supernatants were stored at 220uC.
Table 1. Percent identities and similarities of HPV31, HPV18, and HPV45 L2 epitopes compared to HPV16 L2 epitopes.
HPV31 HPV31 HPV18 HPV18 HPV45 HPV45
Antibody Abbr
a PI
b PS
c PI PS PI PS
anti-P14/27 #2 #1 86% 93% 79% 86% 79% 93%
anti-P18/38 #2 #2 71% 90% 86% 100% 81% 95%
anti-P28/42 #2 #3 67% 80% 73% 93% 73% 87%
anti-P56/75 #1 #4 90% 100% 100% 100% 90% 100%
anti-P61/75 #2 #5 87% 100% 100% 100% 87% 100%
anti-P64/81 #1 #6 83% 89% 83% 83% 72% 83%
anti-P90/111 #1 #7 82% 95% 64% 95% 68% 95%
anti-P96/115 #2 #8 80% 85% 60% 95% 65% 95%
anti-P107/122 #1 #9 63% 69% 38% 69% 44% 69%
anti-P131/144 #2 #10 71% 79% 64% 79% 71% 79%
S910-1 #88 76% 86% 67% 80% 60% 67%
S845-1 #200 74% 84% 55% 73% 55% 73%
RG-1 RG-1 75% 85% 75% 90% 70% 85%
a, Abbreviated names for antibodies for the purposes of figure simplification in this manuscript.
b, Percent identity measured the percent of identical residues in either HPV31, HPV18, or HPV45 L2 epitopes compared to HPV16 L2 epitopes in relation to the length of
the epitope.
c, Percent similarity measured the percent of residues which share amino acid properties in either HPV31, HPV18, or HPV45 L2 epitopes compared to HPV16 L2 epitopes
in relation to the length of the epitope.
N Bold and italicized values indicate the HPV types that are neutralized by the adjacent antibody.
doi:10.1371/journal.pone.0016405.t001
Figure 4. Western blot analysis of Opriprep-purified L1+L2
VLPs. (A) HPV16, HPV31, HPV18, and HPV45 VLPs were Optiprep-
fractionated and fractions were assayed for L2 content by probing
Western blots with anti-HPV16 L2 polyclonal antibody anti-P56/75 #1.
(B) Side-by-side SDS-PAGE gels run with equivalent amounts of HPV45
and HPV31 L1+L2 VLPs from Optiprep fraction #8 were either
Coomassie-stained, or Western blotted with anti-P56/75 #1. L2 and
L1 bands are indicated by brackets (note the small size difference in L2
and the larger size difference in L1). A control lane that represents an
SDS-PAGE gel of Optiprep-purified 293TT cell lysate without capsid
protein was also included for the Coomassie stained samples (—).
doi:10.1371/journal.pone.0016405.g004
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HaCaT [19] cells were seeded at 50,000 cells/well in 24-well
plates in Dulbecco’s modified Eagle’s medium supplemented with
10% fetal bovine serum, 2 mM glutamine, 1 mM pyruvate, 100
units/ml penicillin, and 100 mg/ml streptomycin and grown to
approximately 70% confluence. 50 ml HPV16 crude viral preps
(CVPs) were diluted with cell culture medium to a total volume of
0.5 ml. Medium was aspirated from HaCaT cells and 0.5 ml of
diluted CVPs was added per well. One well on each plate
received 0.5 ml of medium without virus as a negative control.
The cells were incubated with the virus for 48 h at 37uC. mRNA
was harvested with the SurePrep TrueTotal RNA Purification
Kit (Fisher Scientific). DNA contamination of columns was
determined to be insignificant as the optional on-column DNase-I
treatment of extracted mRNA had no effect on downstream
signal. Amplification of both the viral target and endogenous
cellular control target was performed using a duplex format in
0.2 ml, 96-well PCR plates (BIO-RAD) with a total reaction
volume of 25 ml. All reactions containing RNAs from virus-
infected cells were performed in duplicate or triplicate. Reverse
transcription and quantitative PCR were performed in the same
closed tube with approximately 250 ng of total RNA per reaction
using the Quantitect Probe RT-PCR Kit (Qiagen). HPV16,
HPV31, HPV18, and HPV45 E1‘E4 primers are listed in Table
S1. All were used at final concentrations of 4 mM. Fluorogenic,
dual-labeled, HPV16, HPV31, HPV18, and HPV45 probes are
also listed in Table S1. All were utilized at a final concentration of
0.2 mM to detect E1‘E4 DNA. Primers and probe were
developed using Gene Link Software: OligoAnalyzer 1.2, and
OligoExplorer 1.2. TBP primer sequences were obtained from
those previously described [20]. All primers were synthesized by
Integrated DNA Technologies (Coralville, IA). All QRT-PCR
reactions were performed using the iQ5 (BIO-RAD). Cycling
conditions were 50uC for 30 min (reverse transcription) and 95uC
for 15 min, followed by 42 cycles of 94uC for 15 s and 54.5uCf o r
1 min. Amplification efficiencies of each primer set was 93% for
E1‘E4 and 97% for TBP. Relative quantities of viral target
cDNA were determined using REST software. For antibody-
mediated neutralizations, 50 ml of crude viral prep was incubated
for 1 hour at 37uC prior to infection of HaCat cells with a 1:100
dilution of the anti-HPV16 L2 antibodies listed in Table S3. A
1:100 dilution of a polyclonal antibody generated from HPV45
L1/L2 VLPs (#5158, 45 L1/L2) was also used against 10-day
HPV45. The #5158, 45 L1/L2 antibody was a gift from Richard
Roden.
qPCR-based DNA encapsidation assay
To detect endonuclease-resistant genomes in crude viral preps
(CVPs) or Optiprep fractions, only benzonase-treated CVPs were
utilized so that all non-encapsidated genomes were degraded. To
release all encapsidated viral genomes, 10 ml sonicated virus prep
or 20 ml Optiprep fraction was added to 2 ml Proteinase K, 10 ml
10% SDS, and 2 ml pCMV-GFP (140 ng/ml) carrier DNA, and
adjusted to 200 ml with Hirt buffer. Tubes were rotated at 37uC
for 2 hours. Immediately, an equal amount of phenol-chloro-
form-isoamyl alcohol (25:24:1) was added and the DNA was
extracted into the aqueous phase. An equal amount of
chloroform was added to the aqueous phase and again the
DNA was extracted into the aqueous phase. DNA was EtOH
precipitated overnight at 220uC. After centrifugation, the DNA
pellet was washed with 70% EtOH and resuspended in 20 mlT E
overnight. To detect viral genomes or cellular DNA, a Qiagen
Quantitect SYBR Green PCR kit was utilized. Amplification of
the viral target was performed in 0.2 ml, 96-well PCR plates
(BIO-RAD) in a total reaction volume of 25 ml. l mlo fe a c h
endonuclease-resistant viral genome prep was analyzed in
triplicate for each independent experiment. All primers were
used at a final concentration of 0.3 mM. A list of HPV16,
HPV31, HPV18, and HPV45 primers used to amplify a region in
E2 can be seen in Table S2. Oligonucleotides were synthesized by
Integrated DNA Technologies (Coralville, IA). A standard curve
was generated by amplifying 1 mla l i q u o t so f1 0
4,1 0
3,1 0
2, and
10
1 serially-diluted pBSHPV16, pBSHPV31, pBSHPV18, or
pBSHPV45 copy number controls. Acceptable R
2 values for
standard curves were at or above 0.99. A Bio-Rad iQ5 Multicolor
Real-Time qPCR machine and software were utilized for PCR
amplifications and subsequent data analysis. The PCR thermo-
cycling profile was as follows: 15 min. hot-start at 95uC, followed
by 40 cycles at 15 sec. at 94uC, 30 sec. at 52uC, and 30 sec. at
72uC. Data analysis commenced during the extension phase.
Melt curve analyses were performed for all SYBR Green PCR
amplifications to verify specificity of the reaction. Melt curves and
first derivative melt curves were run immediately after the last
PCR cycle. Melt curves were produced by plotting the
fluorescence intensity against temperature as the temperature
was increased from 60 to 95uCa t0 . 5 uC/s. Calculation of the
exact number of endonuclease-resistant viral genomes per 3-raft
crude viral prep was determined by comparing experimental
values to the number of actual genome copies within the serially-
diluted copy number controls.
293TT cell-based VLP production
HPV VLPs were generated in 293TT cells as previously
described [21]. Briefly, 293TT cells, grown to 90% confluence
in T-150 flasks were cotransfected by using Lipofectamine
2000 with 25 mg each of p16L1h (L1 expression plasmid) and
p16L2h (L2 expression plasmid) (7). Cells were split 1:2 at 24 h
posttransfection and harvested 48 h posttransfection. Cell
pellets were resuspended in a total of 750 ml of phosphate-
buffered saline (PBS). Cells were lysed by Dounce homogeni-
zation as in the HPV isolation step described below. MgCl2
was added to a final concentration of 2 mM. Lysates were then
incubated overnight at 37uC to allow maturation (7). Unpack-
aged DNA was digested by adding 0.2% benzonase (Sigma)
and incubating for 1 h at 37 Cu.A f t e rd i g e s t i o n ,N a C lw a s
added to a final concentration of 1 M. Cellular debris was
removed, and virus-containing supernatant was collected after
centrifugation at 10,500 rpm.
Optiprep purification of VLPs
Optiprep purification was performed as described previously
[21]. Briefly, 27, 33, and 39% Optiprep gradients were produced
by underlayering. Gradients were allowed to diffuse for 1 to 2 h at
room temperature. Then, 600 ml of clarified benzonase-treated
virus preps were layered on top of the gradient. Tubes were then
centrifuged in a SW55 rotor (Beckman) at 234,0006g for 3.5 h at
16uC. After centrifugation, 11 500 ml fractions were carefully
collected from the top of each tube.
Immunoblot analysis
Aliquots from Optiprep fractions were boiled for 10 min in 6%
2 mercaptoethanol (2-ME) loading buffer and loaded onto 8 to
10% polyacrylamide gels. For total protein analysis on SDS-PAGE
gels via Coomassie Simply Blue (Invitrogen) staining, manufac-
turer’s instructions were followed. To detect L2, anti-HPV16 L2
polyclonal antibody P56/75 #1 was utilized at a dilution of
1:4,000.
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